Bladder cancer
Open
Phase 1/2
This study is looking at durvalumab in combination with the S-488210/S-488211 vaccine to treat non muscle invasive bladder cancer.
Recruitment start: 25 March 2022
Recruitment end: 31 October 2025
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Mark Linch
University College London (UCL)
CRUK & UCL Cancer Trials Centre
Shionogi & Co Ltd
AstraZeneca
Last reviewed: 09 Sept 2024
CRUK internal database number: 18501